JY09，is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist,constructed with
Exendin-4 and human Immunoglobulin G2 (IgG2) Fc fragment.Preclinical studies show that JY09
exhibit the expected GLP-1-mediated pharmacological effects on insulin secretion,glucose
covering and islet cell recovering,as well as good tolerance and safety.JY09 has been
approved by China food and drug administration(CFDA) to enter the clinical research
stage(Grant number 2016L04254).This study is designed to assess the
safety,tolerability,pharmacokinetics,pharmacodynamics and potential immunogenicity of JY09 in
healthy Chinese volunteers.